- Home
- ABVX vs TSHA Comparison
ABVX vs TSHA Comparison
Compare ABVX & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABVX
- TSHA
- Stock Information
- Founded
- ABVX 2013
- TSHA 2019
- Country
- ABVX France
- TSHA United States
- Employees
- ABVX N/A
- TSHA N/A
- Industry
- ABVX
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- ABVX
- TSHA Health Care
- Exchange
- ABVX Nasdaq
- TSHA Nasdaq
- Market Cap
- ABVX 451.5M
- TSHA 397.8M
- IPO Year
- ABVX N/A
- TSHA 2020
- Fundamental
- Price
- ABVX $6.02
- TSHA $2.71
- Analyst Decision
- ABVX Buy
- TSHA Strong Buy
- Analyst Count
- ABVX 4
- TSHA 7
- Target Price
- ABVX $31.50
- TSHA $7.00
- AVG Volume (30 Days)
- ABVX 193.4K
- TSHA 5.2M
- Earning Date
- ABVX 03-24-2025
- TSHA 05-15-2025
- Dividend Yield
- ABVX N/A
- TSHA N/A
- EPS Growth
- ABVX N/A
- TSHA N/A
- EPS
- ABVX N/A
- TSHA N/A
- Revenue
- ABVX $11,172,999.00
- TSHA $7,224,000.00
- Revenue This Year
- ABVX $284.20
- TSHA N/A
- Revenue Next Year
- ABVX N/A
- TSHA N/A
- P/E Ratio
- ABVX N/A
- TSHA N/A
- Revenue Growth
- ABVX 135.94
- TSHA N/A
- 52 Week Low
- ABVX $4.77
- TSHA $1.05
- 52 Week High
- ABVX $14.71
- TSHA $4.32
- Technical
- Relative Strength Index (RSI)
- ABVX 46.21
- TSHA 60.38
- Support Level
- ABVX $5.59
- TSHA $2.44
- Resistance Level
- ABVX $6.09
- TSHA $2.95
- Average True Range (ATR)
- ABVX 0.33
- TSHA 0.25
- MACD
- ABVX -0.02
- TSHA -0.02
- Stochastic Oscillator
- ABVX 41.15
- TSHA 51.60
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.